our to I Tara Semb. Chief Thanks, everyone our operator. call. quarter XXXX am of Welcome this fiscal on earnings by Financial year joined Officer, first call afternoon's
XX% on In of we thoughts revenue growth closing we you strategy. for which our agenda achieved revenue share period. quarter updated important operational summary before first during you recent questions. XXXX, progress then our in of growth financial release call. me our Tara during initiatives will represented four our for overview with of to the our components million, with earnings as additional quarter some afternoon. Then quarter of for start fiscal respect with discuss first that I’ll Let guidance, then outlook quick our year-over-year. drivers which of as developments strategic first $X.X detailed key the today's quarter growth XXXX of opening an business the the a our results first will our longer-term I some have of our provide a more I'll the XXXX well with identified as and performance in call and our we total this review the press provide
Renuvion million quarter Energy the or cosmetic driven which increased continues revenue to our $X.X Advanced to by by strong total the continues These resignate results global technology, impressive business, around performance sales sales first for in which growth reflected world. in be cosmetic XX% our markets in year-over-year. Our strong surgery demand
in Our business our markets the handpieces the U.S., and utilization cosmetic fulfilling we execution increasing to coverage existing successful adoption also Energy of in are Advanced distributors new drive and strategy partnerships. our the technology penetration international into the our from revenue quarter growth OUS key demand by our expanding first increasing of and of in results by in generators entering distributor demonstrate Renuvion our markets seeing
international agreement total increased Energy total by Advanced saw with sales From or of brand agreement or our Corp Bovie we performance, first million, contributions XXX% Recall XX% business, increased year-over-year. this by was the standpoint, from year-over-year or business entered business our supply to electrosurgical the contributions The expected largely quarter generator increased connection year. geographic driven important OEM in and addition our and in to surgical. total a last that $XXX,XXX by Medical OEM also into in the growth In XX% which sales – August we of U.S. year-over-year. with divestiture in Symmetry our million, growth by and while $X.X sales brand sale from $X.X
Advanced in equipment fact light market. compared of cosmetic This is the were only First first first sales to the as impressive the the our to quarter increase fourth XXX% sales seasonably in sales OEM a U.S. of surgery by Advanced quarter in the with in increase Energy purchasing and especially U.S. mid Energy in pleased single-digits performance were quarter a We due represent quarter capital the XX% driven that tends in XXXX. declined sales. quarter weaker trends to the
our Renuvion for U.S. the based in growth Energy Advanced handpieces. from Our demand utilization benefited strong
we First were distributors from markets, partnerships expected months of in of by driven existing last our than XXXX. which during nine quarter based international into sales for many Advanced demand international products Energy entered utilization stronger with our the
relationships which expectations. new new represented countries the in versus added first our upside quarter, in additional also distributor We
progress our an during highlights, update our quarter, market. surgery into in Advanced our continued U.S. performance cosmetic in also existing strong the we Turning of and clinician positive receive strong recent to Energy and feedback operational operating of business the customers addition the to from new
their technology results as the of our team Our benefits achieved new sales that are be peers. that of well to Renuvion report the potential can motivated and our as customers they adoption after discussing clinician purchase observing members with
patient our notable seeing existing many Renuvion integrating after of customers procedure a into reported their Additionally, volumes practice. uptick in their
continue discuss their new they have patient will tools remarks, we for their the to customers. they clinical cosmetic I are our to into and to effectively that customers practices later in best to integrate support Renuvion my able improve to and technology market technology ensure practices existing As and
with with the made strategic first our regulatory you discuss like we've moment to take during development respect our would first on updating the I strategy. progress quarter Before important to recent to a initiatives, an
On discussed with team year, clearance filed clearance As on our pursuing XXth dermal regulatory regulatory application premarket has on recent for the been XXX(k) of a in for clinical Renuvion last XXX(k) resurfacing use new FDA. specifically notification our earnings the December focused indication we procedures. for a calls,
Renuvion from a evaluated supported reduction of and which data was wrinkles safety rhytides. of multicenter efficacy facial the application single Our prospective arm, for evaluator-blind study, the and by IDE
application, of concerns several their the regarding and During FDA three questions IDE our our aspects of raised study. review clinical
procedures point. performance end and results primary study's FDA versus the First, the dermal resurfacing Renuvion’s questions stated its regarding
XX% deemed of criteria of meet three study or only one have XX.XX% primary sale study no not the follow-up a Wrinkle analysis to of patients events, and it serious adverse plan visit. patients. efficacy did the improvement protocol were the endpoint and greater IDE included Fitzpatrick of at experience the month yielded as the The on statistical While point success
FDA the of this the outcomes one Second, the three centers third, the three the FDA in in in impact centers as outcomes of compared questioned investigational superior other two. variability study deviations achieved investigational protocol at the treatment questioned investigational center. the study the And across to the
how the to this deviations results questioned may protocol the Specifically, superior have center. at investigational obtained FDA the contributed
Following clinical with at post-procedure. center subjects were the treated that comfort procedures, all a this inflammation be skin the prescribed but treat of corticosteroid MEDROL, increase five to patient can used and
X. March application to Following FDA's were otherwise withdrew be March, discussions that review as with we on to period within resolve voluntarily April late would the the able the favorably congressionally have MDUFA issue we ended FDA raised mandated XX-day in our unlikely XXth on
FDA's with clinical the to in areas their areas. view respect we focus understand While these question our three regarding Apyx the does not study, share on
many We the regulatory productive also with team, has process. and which and positive the clinical through interactions engagement FDA's included appreciate our
and Although in by technology we procedures dermal Renuvion disappointed resurfacing to our clearance when we are are pursuing setback, remain this convinced greatly of resurfacing. XXX(k) for used efficacy committed both of and we safety dermal
profile, included terms our IDE study In events. serious safety adverse of no Renuvion
the experienced study as no regarding from investigators. an of the comment concerns study or of in assessed procedure over improvement in expressed FDA safety this appearance by efficacy subjects XX% an the Additionally, the standpoint, itself. And
to correctly the addition, were patients. identify post-treatment over reviewers XX% photographic In of studies able photographs in independent
next develop intend exemption of submit device steps, new a to application. and or investigational we terms In IDE
securing highly our clinical protocol application. on the necessary new teams developing are Our clinical focused for support IDE regulatory and and a
to market clearance sell XXX(k) a recent initiatives. have and With approach methodical new to IDE, a update submission engaged respect additional our taking we an under procedures. our our data are operational resources external Upon will resurfacing dermal to protocol this process. gather with now application turn We additional new receiving support for I'll progress inform and of to for to our the of Renuvion then an strategic clinical clinical that,
respect As market. procedures, our clinical technology this specific and enable physician on target demonstrating the four for Three, in regulatory efficiencies. team safety Two, indication in year focused new that clinical initiative and growing new improve and focused clinical a four resurfacing and for Apyx Renuvion order efforts Renuvion our secure us for Renuvion strategy indications to the surgery dermal our Medical practice evidence cosmetic Number is our With new one, by to footprint strategic our our to cosmetic for first the manufacturing on of outside U.S., formalize enhance regulatory our clearance in regulatory success secure reminder, our efficacy to a customers. us we'll support strategic obtaining expanding particularly procedures. our to has for surgery the sell following our pursue surgery And to market cosmetic addition initiatives large long-term countries in geographic and capabilities markets. will and with position those technology. been
Renuvion market, for unmet clinical each where strategy distributor Importantly, believe U.S. effort has to our Longer-term, to would obtaining clinical the each is licenses our technology on and we focused the country. strong address indications on market. commercial in cosmetic focus in registrations intend owning identify in We in identified also Renuvion. the needs partner an adjustable are a other clearances to to surgery within expand these potential important respective while come years team potential the we market our
we efficacy Building initiative, the second portfolio we XXXX our support the in our technology. and demonstrating to continuing action of late is a Renuvion publish in clinical during XXXX. the on to retrospective are Turning cosmetic develop so to second clinical the work strategic Renuvion’s use completed comprehensive of study half we our of of to demonstrate the subdermal a in how of marketplace, expect technologies examining unique liposuction procedures Renuvion safety method
the customers remain brand during Our this we These practice expectations. customers, efforts received third Renuvion the to which its in designed our surgery initial in our patient from with on praise has was to clinical progress importantly of of enhancing The committed provide enhance year steady cosmetic marketing March supporting enhancing for response launch strong our strategic market effectively to begin market our help to marketplace. quarter their branding dedicated we customers. customers. and surgery cosmetic earnest late exceeded in our in Renuvion to last the brand, clinicians initiative, first efforts the and continue make Renuvion physician more overall We effort our visibility our has to market in support
launched tandem, Renuvion first quarter, patient we In marketing customers being we marketing optimize video released clinician digital which media. across series to a clinician its customer shared of our tips actionable via and web potential also base to first the educate social clinical our Renuvion with portal of provide via new are them multipart their materials, our benefits. raise awareness to and During our
for our begun hosting recently Renuvion building formal Renuvion customers programs, clinician mentor marketing continue In and call train use improve the which We brand, we events, on to or had physician PMPs. to of addition our programs benefits. support to its we
small group on new the then prospective setting. Renuvion a perform educate formal events, our and seeks program the surgeons PMP of clinical their in or directly During benefits ability of This with our more consulting one to use education potential from to and learn customers cases. live a customers peers provide
We They existing customers have are clinician customers our initial as needed. also in training and and clinical educating their new for specialist, invested support of our additional during our dedicated training clinician small which technology procedures team a our to with customers. provide for
our enhancing addition more relationships to efforts. Director fourth Laura of our efficient our and sales their efficiencies manufacturing lastly, improving more specialists on Iversen, connection our the of our handpieces. direction our we initiative by with focus to demand with clinical strategic them reps under are selling and in capabilities of allowing increasing the our their global be also time for generators accommodate customers, Global And In Operations, to to our help
both we chain. our number made Bulgaria year, a improve workflow last improvements facilities, vertically to Clearwater have our at of our important supply the and including Over and integrate efforts operational
During our we in the capacity first Bulgaria manufacturing facility. quarter specifically, expanded our
products, addition in us lowering improving our more expanding long-term ability capacity our manufacturing Bulgaria In a with provides manufacturing costs. produce benefit to of to our
our our that, OUS first leveraging XXXX also quarter With and let this guidance, detail call fiscal are to our our financial turn which directly to afternoon's from Tara distributor greater results our facility Bulgaria over in review in me to to of the shipping streamline operations We discuss we release. Tara? the updated financial partners. Bulgaria U.S. by
